December 17, 2025

Promising Data For Off-the-Shelf Gene-edited Cell Therapy

New clinical results outline patient responses to a donor-derived, gene-edited cell therapy in relapsed and refractory T-cell leukemia

The Medicine Maker

December 12, 2025

Acupuncture May Improve Perceived Cognitive Difficulties in Breast Cancer Survivors

New findings from the phase II ENHANCE clinical trial indicate that both real and sham acupuncture improve breast cancer survivors’ perceived cognitive impairment more effectively than usual care alon...

The ASCO Post

December 11, 2025

Myopia: A Public Health Emergency

Global experts declare childhood myopia a public health emergency in HOYA-led call to action

The Ophthalmologist

December 10, 2025

This Week’s CGT News: Vertex’s Gene Therapies Show Promise in Younger Children

Our latest news roundup reports on new data for Vertex’s exa-cel, funding for a cell therapy for breast cancer, and new technologies for manufacturing

The Medicine Maker

December 09, 2025

Eliminating Barriers to Care for Patients With Intellectual and/or Developmental Disabilities

A recent large, retrospective study by Giblon et al has found that individuals with intellectual and/or developmental disabilities face an increased risk of developing cancer, higher symptom burden on...

The ASCO Post

November 26, 2025

Is Prevention Always Better Than Cure?

German discussion paper calls for greater balance between preventative and curative measures for childhood blindness

The Ophthalmologist

November 20, 2025

New study finds U.S. fluoride exposure linked to better adolescent cognitive performance 

A new study finds typical childhood fluoride exposure is linked to modestly better teen cognitive performance with no later cognitive harm.

ADA News

November 19, 2025

FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas

The MEK inhibitor was approved today for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas. In September 2025, the FDA approved selumetinib capsules a...

The ASCO Post

November 18, 2025

This Week’s Biopharma News: New Restrictions on Sarepta Gene Therapy

Our latest news roundup reports on the FDA’s new “plausible mechanism” pathway, Novartis’s phase III malaria trial, a new gene therapy in Europe, and more.

The Medicine Maker